Location Directory

Clinical trials in Dallas, Texas

This page shows live ClinicalTrials.gov search results for Dallas, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

13791

Shown on this page

Current sort

Institutions in Dallas

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

UT Southwestern Medical Center

Live official records

Open in full search

Conditions: Endometrial Neoplasms
Interventions: olaparib, durvalumab, durvalumab placebo, olaparib placebo, Carboplatin, Paclitaxel; Drug · Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 150 Years · Female only
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 50
States / cities: Tucson, Arizona • Concord, California • La Jolla, California + 45 more

Conditions: HIV-1-infection
Interventions: Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 40
States / cities: Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more

Conditions: Hypertension, Obesity
Interventions: CagriSema, Semaglutide, Cagrilintide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 57
States / cities: Concord, California • Costa Mesa, California • Fullerton, California + 47 more

Conditions: Breast Cancer, Breast Neoplasms
Interventions: Disitamab vedotin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 120
States / cities: Daphne, Alabama • Foley, Alabama • Mobile, Alabama + 96 more

Conditions: Spinal Cord Injuries, PTSD, Post-Traumatic Stress Disorder
Interventions: Brief Prolonged Exposure Therapy, Treatment as Usual; Behavioral
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Metastatic Colorectal Cancer (CRC)
Interventions: Drug: Ivonescimab Injection, Drug: Bevacizumab Injection; Drug
Lead sponsor: Summit Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 112
States / cities: Mobile, Alabama • Tuscaloosa, Alabama • Goodyear, Arizona + 94 more

Conditions: Obesity, Overweight, Osteoarthritis of the Knee
Interventions: Berobenatide, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 39
States / cities: Tempe, Arizona • Escondido, California • Rancho Cucamonga, California + 30 more

Conditions: Upper Facial Lines, Glabellar Lines
Interventions: TrenibotulinumtoxinE and OnabotulinumtoxinA, Placebo, OnabotulinumtoxinA; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 21
States / cities: Birmingham, Alabama • Glendale, Arizona • Newport Beach, California + 17 more

Conditions: Cancer
Interventions: IDE574, Fulvestrant injection; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Santa Monica, California • New Haven, Connecticut • Plantation, Florida + 13 more

Conditions: Primary Biliary Cirrhosis
Interventions: Elafibranor 80mg, Placebo; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 46
States / cities: Chandler, Arizona • Los Angeles, California • Sacramento, California + 34 more

Conditions: Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
Interventions: Pozelimab, Cemdisiran, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 975 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 160
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 126 more

Conditions: Triple-Negative Breast Cancer
Interventions: Pembrolizumab, Sacituzumab tirumotecan, Capecitabine; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2037
U.S. locations: 93
States / cities: Mobile, Alabama • Chandler, Arizona • Fountain Valley, California + 78 more

Clinical trials in Dallas, Texas

Filter and sort this location

Institutions in Dallas

Live official records

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)

A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

Brief Prolonged Exposure Therapy Versus Clinical Standard to Reduce Posttraumatic Stress Post Spinal Cord Injury

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)

A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)